Dataset from Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: A Randomised, Double-blind, Placebo Controlled, Parallel Group, Multi-centre, Multinational Trial With Stratification of Subject to Either 56 or 160 Weeks of Treatment Based on Pre-diabetes Status at Randomisation

This trial is conducted in Africa, Asia, Europe, Oceania, North America and South America.The aim of this clinical trial is to evaluate the potential of liraglutide to induce and maintain weight loss over 56 weeks in obese subjects or overweight subjects with co-morbidities. Furthermore, the aim is to investigate the long term potential of liraglutide to delay the onset of type 2 diabetes in subjects diagnosed with pre-diabetes at baseline.Based on body mass index (BMI) and pre-diabetes status, subjects will be randomised to either 68 weeks (56 weeks of randomised treatment followed by a 12 week re-randomised treatment period) or 160 weeks of treatment (160 week treatment will only be applicable to subjects with pre-diabetes status at baseline).

本试验在非洲、亚洲、欧洲、大洋洲、北美洲及南美洲开展。本临床试验旨在评估利拉鲁肽（liraglutide）在肥胖受试者或合并共病的超重受试者中，诱导并维持56周体重减轻的潜力。此外，本研究旨在探究利拉鲁肽延迟基线确诊为前驱糖尿病的受试者发生2型糖尿病的长期潜力。研究人员将根据受试者的体重指数（BMI）及前驱糖尿病状态，将其随机分配至两种治疗方案：其一为68周治疗方案（即56周随机化治疗后，接续12周重新随机化治疗阶段）；其二为160周治疗方案（该方案仅适用于基线确诊为前驱糖尿病的受试者）。